Hot Features
Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
DEFENCE RETAINS CATO SMS TO ADVISE ON ITS PHASE I CLINICAL TRIAL ON ACCUTOXTM FOR BREAST CANCER Vancouver, BC, Canada, February 16th, 2022 -- InvestorsHub NewsWire Defence Therapeutics Inc...
Defence's AccumTM-HPV vaccine formulation (AccuVAC-PT009) activates a 36-fold higher humoral response compared to Gardasil-9 Vancouver, BC, Canada, January 26th...
Vancouver, BC, Canada -- November 30th 2021 -- InvestorsHub NewsWire -- Defence Therapeutics Inc. (CSE: DTC; FSE: DTC; USOTC: DTCFF) ("Defence" or the...
DEFENCE THERAPEUTICS CANCER VACCINE ACCUVAC-D001 MANUFACTURING TARGETS MELANOMA AND BREAST CANCER Vancouver, BC, Canada -- November 23, 2021 -- InvestorsHub NewsWire...
DEFENCE THERAPEUTICS APPOINTS DR. RIAM SHAMMAA TO ITS BOARD OF DIRECTORS Vancouver, BC, Canada, November 9th, 2021 -- InvestorsHub NewsWire -- Defence Therapeutics Inc. CSE:DTC, USOTC:DTCFF...
VACCINE RESULTS: DEFENCE THERAPEUTICS REPORTS SUCCESSFUL COMPLETION OF ITS COVID-19 VACCINE ACCUVAC-PT001 TOXICOLOGY STUDIES IN RABBITS Vancouver, BC, Canada, November...
DEFENCE THERAPEUTICS ACCUMTM VARIANTS IN VITRO STUDY INCREASES THE POTENCY OF T-DERUXTECAN ADC BY 5-FOLD ON BREAST CANCER Vancouver, BC, Canada, October 13th...
DEFENCE THERAPEUTICS PREPARES FOR PHASE I TRIAL TO TEST ITS DC CANCER VACCINE, ACCUVAC-D002, AGAINST MELANOMA Vancouver, BC, Canada, October 6th, 2021 -- InvestorsHub NewsWire -- Defence...
DEFENCE THERAPEUTICS TO FINALIZE ITS OBJECTIVES TO INITIATE A PHASE I TRIAL AGAINST BREAST CANCER Vancouver, BC, Canada, September 29th, 2021 - InvestorsHub NewsWire -- Defence Therapeutics Inc...
DEFENCE THERAPEUTICS SUCCESSFULLY ENGINEERED AND TESTED A NOVEL INTRANASAL COVID-19 VACCINE FORMULATION IN ANIMALS Vancouver, BC, Canada, September 20th, 2021 -- InvestorsHub NewsWire -- Defence...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.0012 | 0.294045577064 | 0.4081 | 0.4093 | 0.4081 | 1050 | 0.40924286 | CS |
| 4 | -0.00465 | -1.12332407296 | 0.41395 | 0.41395 | 0.40472 | 1033 | 0.40976864 | CS |
| 12 | -0.059 | -12.5987614777 | 0.4683 | 0.4697 | 0.4 | 1107 | 0.43748445 | CS |
| 26 | -0.4407 | -51.8470588235 | 0.85 | 0.85 | 0.4 | 1064 | 0.58362726 | CS |
| 52 | -1.5907 | -79.535 | 2 | 2.07 | 0.4 | 989 | 1.11048891 | CS |
| 156 | -4.0007 | -90.7188208617 | 4.41 | 5.41 | 0.4 | 1067 | 2.03724887 | CS |
| 260 | -2.0907 | -83.628 | 2.5 | 6.4078 | 0.4 | 1190 | 2.81833651 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Premium
